



Trikafta in India

The CDSCO named-patient coordination pathway — indicative 2026

RARE DISEASE · CYSTIC FIBROSIS CFTR MODULATOR

The clinical situation

Trikafta (elexacaftor/tezacaftor/ivacaftor) is a triple-combination CFTR modulator for cystic fibrosis patients aged 2 years and older with at least one F508del mutation or another responsive CFTR variant. Manufactured by Vertex. Oral once-daily morning tablets plus an evening ivacaftor dose. Transaminase monitoring and cataract screening (paediatric) are required. Lifelong therapy; gaps in supply rapidly reverse pulmonary function gains.

The pathway, 5 steps

- 1 Consultation & CFTR genotyping.** Your CF team confirms F508del or other responsive variant and writes the clinical rationale letter.
- 2 Baseline assessment.** Liver function, sweat chloride where useful, pulmonary function, and cataract screening for paediatric patients.
- 3 CDSCO named-patient application.** Rationale, genotype report, patient reference, and dosing plan filed under personal-use import.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner.
- 5 Initiation & monitoring.** Your CF team initiates; transaminases at baseline, 3, 6, and 12 months; continuity planning for lifelong supply.

Indicative economics

Reference US cash-pay range: USD 320,000–340,000 per year (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete CDSCO application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your CF team and CDSCO review, keyed to CFTR genotype and rationale. **Logistics.** Temperature-controlled shipment with importer-of-record handling and continuity planning. **Concierge case lead.** Named point of contact for the family and CF team. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating CF physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Trikafta × India first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/trikafta-india.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team